Furlow Brenda S. 4

Accession 0001415889-22-012330

CIK 0000842023other

View on SEC.gov Company Profile

Filed

Dec 8, 7:00 PM ET

Accepted

Dec 9, 4:48 PM ET

Size

35.7 KB

Accession

0001415889-22-012330

Insider Transaction Report

Form 4

Period: 2022-12-07

BIO-TECHNE CorpTECH

Furlow Brenda S.

SVP - General Counsel

Transactions

Sale
Common Stock
2022-12-07$82.01/sh−800$65,605→ 26,092 total
Exercise/Conversion
Common Stock
2022-12-07$31.26/sh+800$25,010→ 26,892 total
Exercise/Conversion
Stock Options (Right to Buy)
2022-12-08−7,450→ 29,762 total
Exercise: $31.26Exp: 2024-08-09→ Common Stock (7,450 underlying)
Exercise/Conversion
Common Stock
2022-12-08$31.26/sh+7,450$232,906→ 33,542 total
Sale
Common Stock
2022-12-08$82.12/sh−7,450$611,810→ 26,092 total
Exercise/Conversion
Stock Options (Right to Buy)
2022-12-07−800→ 37,212 total
Exercise: $31.26Exp: 2024-08-09→ Common Stock (800 underlying)

Holdings

Restricted Stock Units
→ Common Stock (4,668 underlying)
4,668
Stock Options (Right to Buy)
Exercise: $94.52Exp: 2029-08-15→ Common Stock (24,664 underlying)
24,664
Stock Options (Right to Buy)
Exercise: $44.33Exp: 2025-08-08→ Common Stock (66,248 underlying)
66,248
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock (33,300 underlying)
33,300
Common Stock
(indirect: By Trust)
5,320
Restricted Stock Units
→ Common Stock (6,716 underlying)
6,716
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock
Stock Options (Right to Buy)
Exercise: $120.45Exp: 2028-08-06→ Common Stock (18,240 underlying)
18,240
Common Stock
(indirect: By Trust)
5,320
Stock Options (Right to Buy)
Exercise: $47.60Exp: 2026-08-07→ Common Stock (39,872 underlying)
39,872
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock (29,968 underlying)
29,968
Stock Options (Right to Buy)
Exercise: $47.60Exp: 2026-08-07→ Common Stock (53,160 underlying)
53,160
Stock Options (Right to Buy)
Exercise: $66.97Exp: 2027-08-05→ Common Stock (39,960 underlying)
39,960
Stock Options (Right to Buy)
Exercise: $93.11From: 2022-08-31Exp: 2028-03-01→ Common Stock (43,988 underlying)
43,988
Stock Options (Right to Buy)
Exercise: $120.45Exp: 2028-08-06→ Common Stock (24,320 underlying)
24,320
Restricted Stock Units
→ Common Stock (7,936 underlying)
7,936

Footnotes (12)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from 82.0000 to 82.4900, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F10]Options to purchase 6,080 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
[F11]Options to purchase 6,168 shares vest on each of 8/15/2023 and 8/15/2025 and options to purchase 6,164 shares vest on 8/15/2024 and 8/15/2026.
[F12]2,644 shares vest on each of 8/15/2023 and 8/15/2025, and 2,648 shares vest on 8/15/2024.
[F2]Fully exercisable.
[F3]Options to purchase13,292 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 13,288 shares vest on each of 8/7/2022 and 8/7/2023.
[F4]Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
[F5]Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
[F6]Options to purchase 9,992 shares vest on each of 8/5/2021 and 8/5/2022 and options to purchase 9,988 shares vest on each of 8/5/2023 and 8/5/2024.
[F7]Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
[F8]Options to purchase 11,100 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.
[F9]Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Documents

1 file

4
form4-12092022_091248.xmlPrimary

Issuer

BIO-TECHNE Corp

CIK 0000842023

→

Entity typeother

Related Parties

filerCIK 0001443851

Filing Metadata

Form type: 4
Filed: Dec 8, 7:00 PM ET
Accepted: Dec 9, 4:48 PM ET
Size: 35.7 KB

View on SEC.gov